4.8 Review

I've looked at gut from both sides now: Gastrointestinal tract involvement in the pathogenesis of SARS-CoV-2 and HIV/SIV infections

Journal

FRONTIERS IN IMMUNOLOGY
Volume 13, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2022.899559

Keywords

HIV; human immunodeficiency virus; SIV; SARS-CoV-2; AIDS; acquired immunodeficiency syndrome; COVID; 19; inflammation; microbial translocation; barrier integrity

Categories

Funding

  1. National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases/National Heart, Lung and Blood Institute/National Institute of Allergy and Infectious Diseases
  2. Division of Intramural Research, NIAID
  3. [R01 DK130481]
  4. [R01 DK113919]
  5. [R01 DK119936]
  6. [R01 DK131476]
  7. [RO1 HL117715]
  8. [R01 HL123096]
  9. [R01 HL154862]
  10. [R01 AI119346]

Ask authors/readers for more resources

The diversity and location of microorganisms in the gastrointestinal tract can directly affect viral disease pathogenesis. Infections such as HIV, SIV, and SARS-CoV-2 can cause gastrointestinal pathology, and therapeutic interventions targeting the gastrointestinal tract may improve patient outcomes.
The lumen of the gastrointestinal (GI) tract contains an incredibly diverse and extensive collection of microorganisms that can directly stimulate the immune system. There are significant data to demonstrate that the spatial localization of the microbiome can impact viral disease pathogenesis. Here we discuss recent studies that have investigated causes and consequences of GI tract pathologies in HIV, SIV, and SARS-CoV-2 infections with HIV and SIV initiating GI pathology from the basal side and SARS-CoV-2 from the luminal side. Both these infections result in alterations of the intestinal barrier, leading to microbial translocation, persistent inflammation, and T-cell immune activation. GI tract damage is one of the major contributors to multisystem inflammatory syndrome in SARS-CoV-2-infected individuals and to the incomplete immune restoration in HIV-infected subjects, even in those with robust viral control with antiretroviral therapy. While the causes of GI tract pathologies differ between these virus families, therapeutic interventions to reduce microbial translocation-induced inflammation and improve the integrity of the GI tract may improve the prognoses of infected individuals.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available